Get the Stockscreener App
0.00
100.00%
-3.20
After Hours:
3.17
3.17
+
OncoCyte Corporation stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
See More
Previous Close:
$3.20
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$75.50M
Revenue:
$709.00K
Net Income/Loss:
$-43.14M
P/E Ratio:
0.00
EPS:
-4.54
Net Cash Flow:
$-20.35M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
Name
OncoCyte Corporation
Sector
Industry
Phone
510-775-0515
Address
1010 Atlantic Avenue, Suite 102, Alameda, CA
Compare OCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
0.00 | 75.50M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
OncoCyte Corporation Stock (OCX) Latest News
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - MSN
OncoCyte Corporation Crosses 200 Day MA — Signal or NoiseWeekly Profit Analysis & Verified Swing Trading Watchlist - 선데이타임즈
Can OncoCyte Corporation hit a new high this monthWeekly Profit Summary & Verified Swing Trading Watchlist - Newser
Using Bollinger Bands to evaluate OncoCyte CorporationJuly 2025 Selloffs & Weekly Momentum Picks - Newser
Statistical indicators supporting OncoCyte Corporation’s strengthWeekly Stock Analysis & Daily Entry Point Trade Alerts - Newser
Can OncoCyte Corporation recover in the next quarter2025 Market Outlook & Capital Efficient Trade Techniques - Newser
What indicators show strength in OncoCyte CorporationJuly 2025 Institutional & Verified Trade Idea Suggestions - Newser
Is OncoCyte Corporation trending in predictive chart modelsMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Reversal indicators forming on OncoCyte Corporation stockChart-Based Entry Confirmation for Beginners - Newser
Is OncoCyte Corporation reversing from oversold territoryPortfolio Risk Distribution Analysis Tool - Newser
OncoCyte Corporation Stock Chart Analysis: Bullish or Bearish Pattern FormingBond Market & Safe Entry Point Alerts - Newser
Why OncoCyte Corporation stock attracts strong analyst attentionStable Swing Setup with Safety Analysis - Newser
Is OncoCyte Corporation stock overhyped or has real potentialTechnical Long-Term Outlook and Recap Guide - Newser
Combining machine learning predictions for OncoCyte CorporationExpert-Backed High Yield Stock Watchlist - Newser
Top chart patterns to watch in OncoCyte CorporationEarly Buy Opportunity with Chart Triggers - Newser
What MACD and RSI say about OncoCyte CorporationScalable Strategy with Chart Confirmation - Newser
Using economic indicators to assess OncoCyte Corporation potentialFree Accurate Technical Trend Reversal Picks - Newser
Using data filters to optimize entry into Amgen Inc.Entry Optimization Tool with Screener Logic - Newser
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
Will a bounce in OncoCyte Corporation offer an exitAlpha Trade Flow With Risk Calibration - Newser
How OncoCyte Corporation stock performs during market volatilityWeekly Entry Signal Based Forecast Tool - Newser
Will OncoCyte Corporation benefit from macro trendsFree Low Risk Equity Screener With Results - Newser
Advanced analytics toolkit walkthrough for OncoCyte CorporationChart Confirmation Setup with ROI Signals - Newser
Detecting support and resistance levels for OncoCyte CorporationInvestment Timeline and ROI Summary Report - Newser
Is It Too Late to Sell OncoCyte CorporationConservative Long Term Growth Plans Under Review - beatles.ru
What to expect from OncoCyte Corporation in the next 30 daysMomentum Entry Alerts with Risk Control - Newser
Is OncoCyte Corporation building a consolidation baseAI-Powered Stock Trend Movement Analysis - Newser
OncoCyte Corporation’s volatility index tracking explainedLong-Term Stock Growth Forecast Insights - Newser
What makes OncoCyte Corporation stock price move sharplyScalable Strategy with Chart Confirmation - Newser
How to build a dashboard for OncoCyte Corporation stock3-Day Market Movement Forecast Analysis - Newser
Should I buy OncoCyte Corporation stock before earningsTrading Volume Spike and Reversal Analysis - Newser
What technical models suggest about OncoCyte Corporation’s comebackBuy/Sell Zone Confirmation Technical Analysis - Newser
OncoCyte Corporation Stock (OCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):